Increased demand is causing the shortage that has hit five drugmakers, according to the FDA.
Teva Pharmaceuticals “is continuing to produce to planned demand” for nine products, Novartis’ Sandoz has four on allocation, Rising Pharma has two in short supply but available, Hikma Pharmaceuticals has four “available for current customers” and Aurobindo has four on allocation.
Amoxicillin is an antibiotic that the CDC recommends as a “first-line therapy” for multiple pediatric infections.
The FDA did not list resupply dates, but the ASHP reported all of the products are expected to return to normal levels by the end of 2022. In the ASHP’s post in late October, the shortage included 41 products from Teva, Sandoz and Rising Pharma.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
